A large UK study found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may increase the risk of gastroesophageal reflux disease (GERD) and its complications. Researchers comparted 4,708 adults with type 2 diabetes who began treatment with a GLP-1 RA between 2013 and 2021 to 89,096 patients who started sodium–glucose cotransporter-2 (SGLT-2) inhibitors. They found a 27% increased relative risk of GERD among GLP-1 RA users compared to those on SGLT-2 inhibitors. Early recognition and treatment of GERD could help prevent long-term esophageal complications, especially as use of these drugs continues to expand for diabetes and obesity management. 

Source: Annals of Internal Medicine